This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Vanflyta (quizartinib)
General Description:
Vanflyta (quizartinib) is a prescription medicine indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive.
Vanflyta is a FLT3 inhibitor that works by blocking the activity of the FLT3 receptor tyrosine kinase, a protein involved in the growth and survival of leukemia cells. By inhibiting this pathway, Vanflyta helps slow or stop the proliferation of cancer cells in patients with FLT3-ITD positive AML.
Disease Indications:
Leukemia
Manufacturer:
Daiichi Sankyo Company Limited
Usage:
Oral
Medicine Approved by:
• European Medical Agency (EMA)
• Food and Drug Administration (FDA)
Package:
• 1 bottle with 28 tablets × 17.70 mg
• 1 bottle with 56 tablets × 26.50 mg
Shipping:
Room Temperature Shipping
For this medication, standard shipping applies. This means that a consistent room temperature of 15°C to 25°C is maintained during transit.
How to Access Vanflyta (quizartinib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Vanflyta (quizartinib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
